

Artrya Limited

ACN 624 005 741

Appendix 4D

1 Details of the reporting period and the previous corresponding period

Current period: 1 July 2022 to 31 December 2022

Previous corresponding period: 1 July 2021 to 31 December 2021

2 Results for announcement to the market

Results			%		\$'000
2.1(a)	Revenue from ordinary activities	Remained	0	to	0
2.2	Loss from ordinary activities attributable to members	Down	2.76	to	6,459
2.3	Net loss for the period attributable to members	Down	2.76	to	6,459

2.4 Dividends

Nil

2.5 Record date for dividend entitlement

Not applicable

2.6 Commentary

No dividends have been paid or declared since the end of the previous financial year, nor do the directors recommend the declaration of a dividend.

3 Net tangible assets/(liabilities) per ordinary share

Security	31 Dec 2022	30 June 2022
	(cents)	(cents)
Ordinary shares	38.59	47.24

4 Control gained or lost over entities during the period, and those having material effect

Not applicable

5 Dividend details

Not applicable

6 Dividend or distribution reinvestment plan details

Not applicable

7 Investments in associates and joint ventures

Not applicable

8 Foreign entities

Not applicable

9 Audit

The half-year report is based on accounts which have been subject to review.

ARTRYA™

Consolidated Interim Financial Report

FOR THE HALF-YEAR ENDED 31 DECEMBER 2022

Coronary Artery Disease. We see you.

Contents

Directors' Report	03
Condensed consolidated statement of financial position	06
Condensed consolidated statement of profit or loss and other comprehensive income	07
Condensed consolidated statement of changes in equity	08
Condensed consolidated statement of cash flows	09
Notes to the condensed consolidated interim financial statements	10
Directors' declaration	15
Auditor's Independence Declaration	16
Auditor's Review Report	17

Directors' report

The directors of Artrya Limited ("the Company") present their report together with the consolidated financial statements for the six months ended 31 December 2022 and the review report thereon.

Directors

The names of the Company's directors in office during the half-year and until the date of this report are set out below. Directors were in office for this entire period, unless otherwise stated

Non-Executive

Mr Bernie Ridgeway Independent Chair	Director since 8 February 2021
Dr Jacque Sokolov Non-Executive Director	Director since 1 August 2022

Executive

Mr John Barrington AM Managing Director	Director since 24 January 2018
Mr John Konstantopoulos Executive Director - Product	Director since 24 January 2018

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

Based in Perth, Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Review of operations

Early in the first half of the financial year, management made the commercial decision to cut costs from the business to focus on the areas of greatest immediate return and preserve capital. The earlier cost base, primarily in marketing and operational areas, had been established so the business could move swiftly to market had the United States Food & Drug Administration (FDA) 510(K) application clearance for commercial use of Salix Coronary Anatomy (SCA) been successful. The work accomplished and relationships developed by these areas stands Artrya in a strong position for the future. Those functions can be reactivated quickly when required. Previous spend in those areas has been reallocated into the three strategic areas of product refinement, regulatory preparation and revenue generation. Business development activities continued in Australia and the United Kingdom building on Australian regulatory approval (TGA) already gained and opportunities in the UK.

Scientific activity supporting product refinement, regulatory applications and revenue generation through credible research output also continued with a major award being received at the prestigious Society of Cardiovascular Computed Tomography conference in July 2022.

The strategic decisions taken also came on the back of the broader correction in the capital markets and the re-pricing of pre-revenue companies like Artrya.

Market entry and regulatory approval status

United States

The Food & Drug Administration regulatory approval strategy was redefined based on feedback received from the initial submission. Artrya will pursue both 510(k) and de novo approval pathways commencing early calendar 2023, allowing for earlier 510(k) approval while the longer-term de novo application will run in parallel. While working towards a new FDA application the Company has reduced costs in US operations to enable appropriate investment in the key area of regulatory approval.

The revised approach to the US Food & Drug Administration approval process is moving rapidly with further updates expected in the first half of 2023.

An important development in the US was the announcement that a Current Procedural Terminology (CPT) reimbursement code had been released for AI-driven software that aids in the interpretation of Coronary Computed Tomography Angiography (CCTA). This enables Artrya Salix users to receive immediate reimbursement for the use of the Salix software when commercially launched in the US. United States healthcare is putting high value on AI tools for clinical decision support and is driving adoption by allocating a high reimbursement of US\$900-\$1,000 per CCTA scan for use of the software.

This will significantly accelerate Artrya's entry into the US market and will drive adoption since the facility and practice will share in the reimbursement for Artrya Salix-aided interpretation of CCTAs. Our strong product pipeline will result in more than double this reimbursement once we release software for Fractional Flow Reserve (FFR) because another CPT code has been designated for reimbursement to analyse FFR from CCTA scans.

The allocation of the CPT reimbursement codes significantly strengthens Artrya's ability to rapidly commercialise the SCA product when FDA approval is received.

Australia and New Zealand

The Company focused on the refinement of the SCA product, following learnings and feedback from our pilot site testing program. More than 400 scans per month were being processed through the SCA product allowing for continued refinement and calibration.

The Company worked closely with clinicians to make important refinements to incorporate field experience.

Artrya Salix is already listed on the Australian Register of Therapeutic Goods (ID 347719).

On the basis of the Australian regulatory approval (ARTG 347719), the SCA product received NZ Medsafe registration in July 2022. This will allow the Company to commercialise the product in the New Zealand market.

United Kingdom and Europe

On 27 October 2022, the Company announced it had received regulatory approval for the SCA product in Europe.

The assessment scope of Artrya's European Notified Body (BSI) also includes UKCA certification in accordance with the UK Medical Devices Regulations 2002. Artrya's Salix Artificial Intelligence coronary software met or exceeded all regulatory requirements.

The separate approval notifications for European CE Marking and UKCA certification were delivered within a two-week period in late October and early November, providing significant endorsements of the SCA product's efficacy.

The United Kingdom provides a key market opportunity for the Company. Artrya has a four-year contract in place to supply National Health Service Trust Hospitals throughout the UK with the SCA product. The Company is now working through the next steps with the NHS for access to the Trust Hospitals.

The European regulatory approval also provides a substantial future market opportunity for Artrya. When the CE Mark certification is issued, Artrya is able to market the Salix software in 28 European Economic Area countries.

Senior Appointments

In August 2022, Dr Jacque Sokolov was appointed as a non-executive director to the Artrya Ltd Board.

Dr. Sokolov is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US diversified healthcare management and development company. His company has worked with more than 100 healthcare organisations across multiple US healthcare sectors to develop physician-driven, value-focused solutions in rapidly evolving markets. Dr Sokolov is Chairman and President of Artrya USA Inc and Chairs the Artrya Clinical Advisory Board.

Financials

Net loss for the period was \$6.5 million (net loss for half-year to 31 December 2021: \$6.6 million).

The Company's cash balance was \$26.9 million as of 31 December 2022, The Company's cash balance, including term deposits, was \$35.6 million as of 30 June 2022.

Net operating cash outflow for the period was \$6.3 million (2021: \$4.9 million), mostly relating to continued product research, market entry and commercialisation, and administration expenses.

During the half-year, Artrya benefitted from the Federal Government's BMTH 3.0 grant program with \$0.2 million received during the half-year for expenditure incurred in the prior year. The Company continues to qualify for a cash offset from the R&D tax incentive scheme.

Lead auditor's independence declaration

The lead auditor's independence declaration is set out on page 16 and forms part of the directors' report for the six months ended 31 December 2022.

Subsequent events

No matter or circumstance has occurred after the half-year end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial years.

Rounding off

The Company is of a kind referred to in *ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191*, and in accordance with that instrument amounts in the condensed consolidated financial statement and directors' report have been rounded off to the nearest thousand dollars, unless otherwise stated.

Signed in accordance with a resolution of the directors:



John Barrington AM
Managing Director and CEO

Dated at Perth this 21st day of February 2023

Condensed consolidated statement of financial position

As at 31 December 2022

<i>In thousands of dollars</i>	Note	31 Dec 2022	30 Jun 2022
Assets			
Current assets			
Cash and cash equivalents		26,852	15,285
Other investments		274	20,274
Trade and other receivables		3,452	1,986
Prepayments		90	325
Total current assets		30,668	37,870
Non-current assets			
Property, plant, and equipment	5	1,838	1,805
Intangible assets	6	4,854	3,675
Right-of-use assets		464	519
Total non-current assets		7,156	5,999
Total assets		37,824	43,869
Liabilities			
Current liabilities			
Trade and other payables		1,072	1,492
Lease liabilities		271	220
Employee benefits		386	351
Total current liabilities		1,729	2,063
Non-current liabilities			
Lease liabilities		963	1,148
Employee benefits		19	18
Total non-current liabilities		982	1,166
Total liabilities		2,711	3,229
Net assets		35,113	40,640
Equity			
Share capital	10	56,425	56,398
Share based payments reserve	11	7,873	6,973
Foreign currency translation reserve		10	5
Accumulated losses		(29,195)	(22,736)
Total equity		35,113	40,640

The notes on pages 10 to 14 are an integral part of these condensed consolidated interim financial statements.

Condensed consolidated statement of profit or loss and other comprehensive income

For the half-year ended 31 December 2022

<i>In thousands of dollars</i>	Note	For the six months ended	
		31 Dec 2022	31 Dec 2021
Revenue		-	-
Other income	7	588	55
Employee benefits expense	8	(2,745)	(3,018)
Product development expenses		(2,552)	(789)
Business development expenses		(511)	(1,281)
General and administrative expenses		(1,068)	(993)
Depreciation and amortisation		(251)	(21)
Foreign currency gains/(losses)		(9)	(27)
Capital raising costs		-	(573)
Operating loss		(6,548)	(6,647)
Finance income		128	6
Finance costs		(27)	(1)
Loss before tax		(6,447)	(6,642)
Income tax expense		(12)	-
Loss for the period		(6,459)	(6,642)
Other comprehensive income		5	-
Total comprehensive loss for the period		(6,454)	(6,642)
Loss per share (cents):			
Basic loss per share (cents)	9	(8.24)	(11.97)
Diluted loss per share (cents)	9	(8.24)	(11.97)

The notes on pages 10 to 14 are an integral part of these condensed consolidated interim financial statements.

Condensed consolidated statement of changes in equity

For the half-year ended 31 December 2022

<i>In thousands of dollars</i>	Note	Share capital	Accumulated losses	Share based payments reserve	Foreign currency translation reserve	Total
Balance at 1 July 2022		56,398	(22,736)	6,973	5	40,640
Total comprehensive loss for the period						
Loss for the period		-	(6,459)	-	-	(6,459)
Other comprehensive income		-	-	-	5	5
Total comprehensive loss for the period		-	(6,459)	-	5	(6,454)
Contributions by and distributions to owners of the Company						
Share options exercised	10	10	-	-	-	10
Equity settled share-based payments	11,12	17	-	900	-	917
Total contributions by owners of the Company		27	-	900	-	927
Balance at 31 December 2022		56,425	(29,195)	7,873	10	35,113

<i>In thousands of dollars</i>	Note	Share capital	Accumulated losses	Share based payments reserve	Total
Balance at 1 July 2021		18,106	(5,581)	1,379	13,904
Total comprehensive loss for the period					
Loss for the period		-	(6,642)	-	(6,642)
Total comprehensive loss for the period		-	(6,642)	-	(6,642)
Contributions by and distributions to owners of the Company					
Issue of share capital (net of share issue costs)		37,746	-	-	37,746
Share options exercised		10	-	-	10
Equity settled share-based payments	12	-	-	1,556	1,556
Total contributions by owners of the Company		37,756	-	1,556	39,312
Balance at 31 December 2021		55,862	(12,223)	2,935	46,574

The notes on pages 10 to 14 are an integral part of these condensed consolidated interim financial statements.

Condensed consolidated statement of cash flows

For the half-year ended 31 December 2022

<i>In thousands of dollars</i>	Note	For the six months ended	
		31 Dec 2022	31 Dec 2021
Cash flows from operating activities			
Payments to suppliers and employees		(6,275)	(4,914)
Interest paid		(25)	-
Income taxes paid		(12)	-
Government grants and tax incentives		-	-
Net cash used in operating activities		(6,312)	(4,914)
Cash flows from investing activities			
Interest received		171	6
Acquisition of property, plant and equipment	5	(229)	(133)
Payments for intangible assets		(2,180)	(2,190)
Government grants received		236	147
Proceeds from other financial assets		20,000	-
Acquisition of other financial assets		-	(29,125)
Net cash used in investing activities		17,998	(31,295)
Cash flows from financing activities			
Proceeds from issue of equity securities		10	40,010
Costs of fund raising		-	(2,143)
Repayment of lease liability		(134)	-
Net cash from financing activities		(124)	37,867
Net increase (decrease) in cash and equivalents		11,562	1,658
Cash and cash equivalents at 1 July		15,285	12,982
Effect of exchange rate fluctuations on cash held		5	-
Cash and cash equivalents at 31 December		26,852	14,640

The notes on pages 10 to 14 are an integral part of these condensed consolidated interim financial statements.

Notes to the condensed consolidated interim financial statements

1 Reporting entity

Artrya Limited (“the Company”) is a Company domiciled in Australia. These condensed consolidated interim financial statements (“interim financial statements”) as at and for the six months ended 31 December 2022 comprise the Company and its subsidiaries (together referred to as “the Group”). The Group is primarily involved in the development of medical technology using artificial intelligence to more accurately identify patients at risk of coronary artery disease.

The consolidated annual financial statements of the Group as at and for the year ended 30 June 2022 are available upon request from the Company’s registered office at 1257 Hay St, West Perth 6005, or <https://www.artrya.com>.

2 Basis of preparation

These interim financial statements are general purpose financial statements prepared in accordance with AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

They do not contain all of the information required for a complete set of annual financial statements. However, selected explanatory notes are led to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual consolidated financial statements as at and for the year ended 30 June 2022.

These interim financial statements were authorised for issue by the Company’s Board of Directors on 21 February 2023.

The Company is of a kind referred to in *ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191* and in accordance with that instrument, amounts in the condensed consolidated financial statement and directors’ report have been rounded off to the nearest thousand dollars, unless otherwise stated.

3 Significant accounting policies

The accounting policies applied in the interim financial statements are those applied in the Group’s consolidated financial statements for the year ended 30 June 2022.

4 Standards issued but not yet effective

A number of new standards and amendments to standards are effective for annual periods beginning after 1 January 2022 and earlier application is permitted. The Group has not early adopted any of the forthcoming new or amended standards in preparing these condensed consolidated interim financial statements.

5 Property, plant and equipment

<i>In thousands of dollars</i>	31 Dec 2022	30 Jun 2022
Carrying amount beginning of period	1,805	98
Additions	229	1,879
Disposals and write-offs	-	(22)
Depreciation	(196)	(150)
Carrying amount end of period	1,838	1,805

6 Intangible assets

<i>In thousands of dollars</i>	31 Dec 2022	30 Jun 2022
Carrying amount beginning of period	3,675	517
Additions	2,310	4,501
Amortisation	-	-
Government grants receivable	(1,131)	(1,343)
Carrying amount end of period	4,854	3,675

7 Other income

<i>In thousands of dollars</i>	Six months to 31 Dec 2022	Six months to 31 Dec 2021
Government grants	588	55
	588	55

8 Employee benefits

<i>In thousands of dollars</i>	Six months to 31 Dec 2022	Six months to 31 Dec 2021
Wages and salaries	2,097	1,347
Superannuation	211	115
Share based payment expenses (note 11)	215	1,556
Other employee related expenses	222	-
	2,745	3,018

9 Earnings per share

	Six months to 31 Dec 2022	Six months to 31 Dec 2021
(a) Basic earnings per share		
Loss attributable to ordinary equity holders (cents)	(8.24)	(11.97)
(b) Diluted earnings per share		
Loss attributable to ordinary equity holders (cents)	(8.24)	(11.97)
(c) Diluted earnings per share		
Loss after tax from continuing operations (\$'000)	(6,459)	(6,642)
(d) Weighted average number of shares for the period	78,344,853	55,478,310

Potential ordinary shares are not considered dilutive as their conversion does not show an inferior view of the earnings performance of the Company. As such, diluted earnings per share are the same as basic earnings per share.

10 Share capital

	Ordinary shares (\$'000)		Number of shares	
	31 Dec 2022	30 Jun 2022	31 Dec 2022	30 Jun 2022
On issue at start of the period	56,398	18,106	78,247,590	48,482,960
Issued	-	40,010	-	29,629,630
Equity settled share-based payments	17	-	21,403	-
Exercise of options	10	-	135,000	135,000
Share issue costs	-	(1,718)	-	-
On issue at end of the period	56,425	56,398	78,403,993	78,247,590

11 Share-based payments reserve

The cost of options and performance rights is recognised as an expense with a corresponding increase in equity over the vesting period. The cost of options and performance rights granted prior to and during the period were recognised in the accounts as follows.

<i>In thousands of dollars</i>	Six months to 31 Dec 2022	Six months to 31 Dec 2021
Share-based payments reserve at start of period	6,973	1,379
Share-based payments expensed during the period	921	1,556
Share-based payments lapsed/forfeited during the period	(21)	-
Share-based payments reserve at end of period	7,873	2,935

12 Share-based payments

<i>In thousands of dollars</i>	Six months to 31 Dec 2022	Six months to 31 Dec 2021
Employee benefits expense		
- Share-based payments expensed during the period	236	1,556
- Share-based payments lapsed/forfeited during the period	(21)	-
	215	1,556
Product development expenses		
- Share-based payments expensed during the period	688	-
	688	-
Share-based payments	903	1,556

Shares

On 1 November 2022, 4,113 shares were granted to employees under the Company's Employee Incentive Award Plan (EIAP). The shares have a value of \$3,000 and an escrow period of 3 years. On 1 July 2022, 17,290 shares with a value of \$14,000 were issued to employees under the EIAP.

Options

During the half-year a number of options were granted. The details of the options and the factors and assumptions used in determining the fair value of the options are listed below.

Grant Date	Option Life	Pricing Model	Fair value per option	Exercise price	Price of shares on grant date	Expected volatility (iv)	Risk free interest rate	Dividend yield
500,000(i) 1 Jul 2022	5 years	Black Scholes	\$0.3033	\$1.500	\$0.700	70%	3.24%	0%
2,000,000 (i) 14 Sep 2022	4.43 years	Black Scholes	\$0.2645	\$1.500	\$0.600	80%	3.38%	0%
325,000 (ii) 19 Sep 2022	5 years	Black Scholes	\$0.3103	\$1.350	\$0.610	80%	3.48%	0%
325,000 (ii) 19 Sep 2022	5 years	Black Scholes	\$0.2144	\$3.000	\$0.610	80%	3.48%	0%
325,000 (ii) 19 Sep 2022	5 years	Black Scholes	\$0.1587	\$5.000	\$0.610	80%	3.48%	0%

- i) Options were granted to consultants in respect of clinical consulting services. The options are not subject to any vesting conditions and have been expensed immediately.
- ii) Options were granted to an employee. The options vest after 6 months of continued employment service, from the option issue date. The terms were partially accepted during the 2022 financial year and fully accepted on 19 September 2022. The estimate in the 2022 annual report has been revised in this half year report, based on a grant date of 19 September 2022.
- iii) Expected volatility was based on the historical volatility of comparable companies and estimates by option valuation experts.

As at 31 December 2022 the Group had the following options on issue:

Number of Options Outstanding	Exercise Price	Expiry Date
6,000,000 unlisted	\$0.001	25-Mar-2024
270,000 unlisted	\$0.075	10-Jan-2025
1,300,000 unlisted	\$0.056	23-Sep-2025
220,000 unlisted	\$0.075	27-Nov-2025
1,226,752 unlisted	\$0.075	31-Dec-2025
500,000 unlisted	\$1.000	23-Apr-2026
5,500,000 unlisted	\$1.000	09-Jul-2026
1,300,000 unlisted	\$1.350	13-Jan-2027
1,300,000 unlisted	\$3.000	13-Jan-2027
1,300,000 unlisted	\$5.000	13-Jan-2027
650,000 unlisted	\$1.350	28-Mar-2027
650,000 unlisted	\$3.000	28-Mar-2027
650,000 unlisted	\$5.000	28-Mar-2027
325,000 unlisted	\$1.350	20-Jun-2027
325,000 unlisted	\$3.000	20-Jun-2027
325,000 unlisted	\$5.000	20-Jun-2027
500,000 unlisted	\$1.500	01-Jul-2027
2,000,000 unlisted	\$1.500	16-Feb-2027

Performance rights

During the half-year a number of performance rights were granted. The details of the performance rights and the factors and assumptions used in determining the fair value of the performance rights are listed below.

Grant Date	Performance Right life	Pricing Model	Fair value per right	Share price barrier	Price of shares on grant date	Expected volatility (iii)	Risk free interest rate	Dividend yield
77,161 (i) 1 Jul 2022	2.00 years	Monte Carlo	\$0.156	\$2.556	\$0.700	70%	2.59%	0%
77,160 (ii) 1 Jul 2022	3.00 years	Monte Carlo	\$0.138	\$4.473	\$0.700	70%	3.00%	0%
77,161 (i) 5 Jul 2022	1.99 years	Monte Carlo	\$0.140	\$2.556	\$0.670	70%	2.58%	0%
77,160 (ii) 5 Jul 2022	2.99 years	Monte Carlo	\$0.125	\$4.473	\$0.670	70%	2.98%	0%
219,908 (i) 14 Nov 2022	2.63 years	Monte Carlo	\$0.162	\$2.551	\$0.69	80%	3.17%	0%
219,907 (ii) 14 Nov 2022	2.63 years	Monte Carlo	\$0.162	\$4.464	\$0.69	80%	3.26%	0%

- (i) 374,230 rights vest when the Company achieves a market capitalisation of \$200 million by 30 June 2024 and of those granted in July, the contractor has remained in service until 30 June 2025. For those granted in November 22, the employee has remained in service until 30 June 2024.
- (ii) 374,227 rights vest when the Company achieves a market capitalisation of \$350 million by 30 June 2025 and remains employed at this date.
- (iii) Expected volatility was based on the historical volatility of comparable companies and estimates by option valuation experts.

As at 31 December 2022 the Group had the following performance rights on issue:

Number of Performance Rights Outstanding	Number Vested	Expiry Date
792,317 (i)	-	30 Jun 2027
792,314 (ii)	-	30 Jun 2027

- (i) 792,317 rights vest when the Company achieves a market capitalisation of \$200 million by 30 June 2024.
- (ii) 792,314 rights vest when the Company achieves a market capitalisation of \$350 million by 30 June 2025.

13 Controlled entities

Subsidiaries	Country of incorporation	Six months to 31 Dec 2022 %	Six months to 31 Dec 2021 %
Artrya Global Pty Ltd	Australia	100	100
Artrya USA Inc.	USA	100	-
Artrya UK Limited (incorporated 16 September 2022)	UK	100	-

14 Segment reporting

The Group determines and presents operating segments based on the information that internally is provided to the Board of directors (“the Board”), who is the Group’s chief operating decision maker.

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. All operating segments’ operating results are regularly reviewed by the Company’s Board to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

Segment results that are reported to the Board include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. All significant operating decisions are based upon analysis of the Group as one segment. The financial results of this segment are equivalent to the financial statements of the Group as a whole. The accounting policies applied for internal reporting purposes are consistent with those applied in preparation of the financial statements.

15 Contingencies

In the opinion of management, the Group did not have any contingencies at 31 December 2022 (31 December 2021: none).

16 Commitments

In the opinion of management, the Group did not have any commitments at 31 December 2022 (31 December 2021: none).

17 Subsequent events

No matter or circumstance has occurred after the half-year end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial years.

Directors' declaration

In the opinion of the directors of Artrya Limited ("the Company")

1. The condensed consolidated financial statements and notes set out on pages 6 to 14, are in accordance with the *Corporations Act 2001* including:
 - a. Giving a true and fair view of the Group's financial position as at 31 December 2022 and of its performance for the six-month period ended on that date, and
 - b. Complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*, and
2. There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors:



John Barrington AM
Managing Director and CEO

Dated at Perth this 21st day of February 2023



Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of Artrya Limited

I declare that, to the best of my knowledge and belief, in relation to the review of Artrya Limited for the half-year ended 31 December 2022 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- ii. no contraventions of any applicable code of professional conduct in relation to the review.


KPMG


John Ward
Partner

Perth
21 February 2023



Independent Auditor's Review Report

To the shareholders of Artrya Limited

Conclusion

We have reviewed the accompanying **Interim Financial Report** of Artrya Limited.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the Interim Financial Report of Artrya Limited does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the **Group's** financial position as at 31 December 2022 and of its performance for the Half-year ended on that date; and
- complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

The **Interim Financial Report** comprises:

- Condensed consolidated statement of financial position as at 31 December 2022
- Condensed consolidated statement of profit or loss and other comprehensive income, Condensed consolidated statement of changes in equity and Condensed consolidated statement of cash flows for the Half-year ended on that date
- Notes 1 to 17 comprising a summary of significant accounting policies and other explanatory information
- The Directors' Declaration.

The **Group** comprises Artrya Limited (the Company) and the entities it controlled at the Half year's end or from time to time during the Half-year.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with these requirements.



Responsibilities of the Directors for the Interim Financial Report

The Directors of the Company are responsible for:

- the preparation of the Interim Financial Report that gives a true and fair view in accordance with *Australian Accounting Standards* and the *Corporations Act 2001*
- such internal control as the Directors determine is necessary to enable the preparation of the Interim Financial Report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Interim Financial Report

Our responsibility is to express a conclusion on the Interim Financial Report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the Interim Financial Report does not comply with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2022 and its performance for the Half-Year Period ended on that date, and complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a Half-year Financial Report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with *Australian Auditing Standards* and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

KPMG

John Ward

Partner

Perth

21 February 2023

ARTRYA™